Fragile X Syndrome (FXS) is one of the most common causes of hereditary cognitive disability in humans. This is due to a genetic modification on the X chromosome, the mutation of an expanding trinucleotide repeats in the FMR1 gene (fragile X mental retardation 1). Disability, which is counted among X-linked mental retardation, can vary widely in severity, ranging from mild learning difficulties to extreme cognitive impairment. It is estimated that approximately 71,000 people in the United States suffer from FXS.
Our Biotech company is developing the first and only pharmaceutically-manufactured CBD gel formulated as a patent-protected permeation-enhanced clear gel, designed to provide controlled drug delivery into the bloodstream transdermally (i.e. through the skin).
Recent studies suggest that Fragile X Syndrome (FXS) and other neuropsychiatric conditions may be associated with a disruption in the endocannabinoid (EC) system. Clinical and anecdotal data suggest that CBD may modulate the EC system and improve certain core social and behavioral symptoms, including social avoidance (prefers isolation from others, prefers solitary activities, avoids new social activities), irritability (aggressive to others, tantrums/outbursts, and stubbornness), social unresponsiveness/lethargy (lack of attention/interaction, inactive/lack of movement and can resist physical contact), and anxiety.
Background information‘s about Fragile X Syndrome (FXS)
Fragile X-associated disorders (FXD) is a family of genetic conditions that can affect individuals in a variety of ways. FXS could cause intellectual disability, anxiety disorders, social avoidance, behavioral and learning challenges and various physical characteristics. It is the leading known genetic cause of both inherited intellectual disability and autism spectrum disorder.
The behavioral symptoms of FXS are linked to deficiencies in the endocannabinoid (EC) system. ECs form a system of neurotransmitters regulating emotional responses, behavioral reactivity to context, and social interaction. FXS patients are born with a mutation in a gene called the Fragile X Mental Retardation Gene, or FMR1, which leads to dysregulation of the EC system, resulting in the core cognitive, social, and behavioral symptoms seen in FXS.
The impairment can range from learning disabilities to more severe cognitive or intellectual disabilities. Patients with FXS exhibit autism-like symptoms including social anxiety and avoidance, cognitive impairment, intellectual disability, anxiety and mood swings, attention deficit, irritability and increased risk for aggression.
The company received Fast Track Designation for it’s gel in treatment of behavioral symptoms associated with FXS.
As we understand is not about the healing of the Fragile X Syndrome (FXS), but about the treatment of behavioral symptoms or increase the quality of life of the sick people! We hope that the company will announce the first positive results of clinical trials in the first half of 2020!
Please read more about our new model portfolio company by subscribing to our free newsletter now! After registering, you will receive your password to access our premium content area https://cannabisradar.info/premium-content/ – you will be able to download all older newsletter issues, trade signals and company introductions!
The Cannabisradar-Team wishes you an nice day!